Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Axsome Therapeutics, Inc. | axsm-20161231ex32223ef5b.htm |
| EX-32.1 - EX-32.1 - Axsome Therapeutics, Inc. | axsm-20161231ex3218334b9.htm |
| EX-31.2 - EX-31.2 - Axsome Therapeutics, Inc. | axsm-20161231ex312733e80.htm |
| EX-31.1 - EX-31.1 - Axsome Therapeutics, Inc. | axsm-20161231ex311e1c4a4.htm |
| 10-K - 10-K - Axsome Therapeutics, Inc. | axsm-20161231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement
|
· |
Form S-8 (No. 333-208579) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan, and |
|
· |
Form S-3 (No. 333-214859) of Axsome Therapeutics, Inc. and in the related Prospectus |
of our report dated March 7, 2017, with respect to the consolidated financial statements of Axsome Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2016.
|
|
/s/ Ernst & Young LLP |
|
|
|
|
New York, NY |
|
|
March 7, 2017 |
|